These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30359121)

  • 41. EMPA-REG OUTCOME: The Cardiologist's Point of View.
    Pham SV; Chilton R
    Am J Med; 2017 Jun; 130(6S):S57-S62. PubMed ID: 28526181
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Implications of the EMPA-REG Trial for Clinical Care and Research.
    Stamatouli AM; Inzucchi SE
    Curr Diab Rep; 2016 Dec; 16(12):131. PubMed ID: 27812962
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke.
    Gerstein H; Jaeschke R
    Pol Arch Med Wewn; 2016 Oct; 126(10):803-805. PubMed ID: 27872459
    [No Abstract]   [Full Text] [Related]  

  • 44. SGLT2 inhibitor empagliflozin: finally at the latter stage of understanding?
    Chan GCW; Tang SCW
    Kidney Int; 2018 Jan; 93(1):22-24. PubMed ID: 29291819
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Empagliflozin: A Review in Type 2 Diabetes.
    Frampton JE
    Drugs; 2018 Jul; 78(10):1037-1048. PubMed ID: 29946963
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality.
    Arbel R; Hammerman A; Azuri J
    Am J Cardiol; 2018 Sep; 122(6):981-984. PubMed ID: 30075890
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Introduction.
    Chilton R
    Am J Med; 2017 Jun; 130(6S):S1-S3. PubMed ID: 28526180
    [No Abstract]   [Full Text] [Related]  

  • 49. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
    Scheen AJ
    Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329
    [TBL] [Abstract][Full Text] [Related]  

  • 50. EMPA-REG OUTCOME: The Cardiologist's Point of View.
    Pham SV; Chilton RJ
    Am J Cardiol; 2017 Jul; 120(1S):S53-S58. PubMed ID: 28606345
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SGLT2 inhibitors: new reports.
    Med Lett Drugs Ther; 2015 Oct; 57(1479):139-40. PubMed ID: 26445203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review: Dapagliflozin increases, and empagliflozin reduces, adverse renal events in type 2 diabetes.
    Nguyen JT; Molony DA
    Ann Intern Med; 2017 Jul; 167(2):JC5. PubMed ID: 28715827
    [No Abstract]   [Full Text] [Related]  

  • 53. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].
    Zechmann S
    Praxis (Bern 1994); 2016 Mar; 105(6):349-50. PubMed ID: 26980688
    [No Abstract]   [Full Text] [Related]  

  • 55. The safety of empagliflozin plus metformin for the treatment of type 2 diabetes.
    Scheen AJ
    Expert Opin Drug Saf; 2018 Aug; 17(8):837-848. PubMed ID: 30068236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The authors reply.
    Mayer GJ; Wanner C; Weir MR; Inzucchi SE; Koitka-Weber A; Hantel S; von Eynatten M; Zinman B; Cherney DZI
    Kidney Int; 2020 Jan; 97(1):213-214. PubMed ID: 31901342
    [No Abstract]   [Full Text] [Related]  

  • 57. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
    Aronson R
    Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    Perreault L
    Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
    Staels B
    Am J Med; 2017 Jun; 130(6S):S30-S39. PubMed ID: 28526184
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
    Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
    J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.